Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H16N4O6.ClH |
| Molecular Weight | 360.75 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[O-][N+](=O)C1=CC=C(O1)\C=N\N2CC(CN3CCOCC3)OC2=O
InChI
InChIKey=PPSVFZXMDMUIGB-FJUODKGNSA-N
InChI=1S/C13H16N4O6.ClH/c18-13-16(14-7-10-1-2-12(22-10)17(19)20)9-11(23-13)8-15-3-5-21-6-4-15;/h1-2,7,11H,3-6,8-9H2;1H/b14-7+;
Furaltadone is a veterinary product, which is marketed for the treatment and control of salmonella infection of poultry. In 1960th was investigated the antibacterial properties of this drug against human Rhodesian sleeping sickness. In three cases treated, two were apparently curated and the third relapsed. No toxic effects attributable to the product had been observed. However, the further investigation of the furaltadone in human was not provided.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antiprotozoals effective in vitro against the scuticociliate fish pathogen Philasterides dicentrarchi. | 2002-06-03 |
|
| Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. | 2000-12 |
|
| The therapeutic effect of 16 antimicrobial agents on Cryptosporidium infection in mice. | 1982-04 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13681531
oral: 250 mg every 6 hour
intravenous: 500 mg
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9576185
Created by
admin on Mon Mar 31 18:33:47 GMT 2025 , Edited by admin on Mon Mar 31 18:33:47 GMT 2025
|
PRIMARY | |||
|
37Q02H7JT2
Created by
admin on Mon Mar 31 18:33:47 GMT 2025 , Edited by admin on Mon Mar 31 18:33:47 GMT 2025
|
PRIMARY | |||
|
223-169-4
Created by
admin on Mon Mar 31 18:33:47 GMT 2025 , Edited by admin on Mon Mar 31 18:33:47 GMT 2025
|
PRIMARY | |||
|
SUB02285MIG
Created by
admin on Mon Mar 31 18:33:47 GMT 2025 , Edited by admin on Mon Mar 31 18:33:47 GMT 2025
|
PRIMARY | |||
|
DTXSID5045380
Created by
admin on Mon Mar 31 18:33:47 GMT 2025 , Edited by admin on Mon Mar 31 18:33:47 GMT 2025
|
PRIMARY | |||
|
100000087020
Created by
admin on Mon Mar 31 18:33:47 GMT 2025 , Edited by admin on Mon Mar 31 18:33:47 GMT 2025
|
PRIMARY | |||
|
3759-92-0
Created by
admin on Mon Mar 31 18:33:47 GMT 2025 , Edited by admin on Mon Mar 31 18:33:47 GMT 2025
|
PRIMARY | |||
|
53270
Created by
admin on Mon Mar 31 18:33:47 GMT 2025 , Edited by admin on Mon Mar 31 18:33:47 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD